| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5003 | 2011 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3188 | 2013 |
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1676 | 2012 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1535 | 2015 |
| Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma E Olsen, M Duvic, A Frankel, Y Kim, A Martin, E Vonderheid, B Jegasothy, ... Journal of Clinical Oncology 19 (2), 376-388, 2001 | 779 | 2001 |
| Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer G Attard, AHM Reid, R A'Hern, C Parker, NB Oommen, E Folkerd, ... Journal of clinical oncology 27 (23), 3742-3748, 2009 | 727 | 2009 |
| Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer G Attard, JF Swennenhuis, D Olmos, AHM Reid, E Vickers, R A'Hern, ... Cancer research 69 (7), 2912-2918, 2009 | 683 | 2009 |
| Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ... Journal of Clinical Oncology 28 (9), 1496, 2010 | 536 | 2010 |
| Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate AHM Reid, G Attard, DC Danila, NB Oommen, D Olmos, PC Fong, ... Journal of clinical oncology 28 (9), 1489, 2010 | 512 | 2010 |
| Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior … CJ Ryan, MR Smith, L Fong, JE Rosenberg, P Kantoff, F Raynaud, ... Journal of clinical oncology 28 (9), 1481, 2010 | 495 | 2010 |
| Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma K Van Besien, FR Loberiza Jr, R Bajorunaite, JO Armitage, A Bashey, ... Blood 102 (10), 3521-3529, 2003 | 444 | 2003 |
| Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer HI Scher, G Heller, A Molina, G Attard, DC Danila, X Jia, W Peng, ... Journal of clinical oncology 33 (12), 1348, 2015 | 402 | 2015 |
| Solid cancers after bone marrow transplantation S Bhatia, AD Louie, R Bhatia, MR O’Donnell, H Fung, A Kashyap, ... Journal of Clinical Oncology 19 (2), 464-471, 2001 | 357 | 2001 |
| Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ... European urology 66 (5), 815-825, 2014 | 343 | 2014 |
| Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors A Krishnan, S Bhatia, ML Slovak, DA Arber, JC Niland, A Nademanee, ... Blood, The Journal of the American Society of Hematology 95 (5), 1588-1593, 2000 | 340 | 2000 |
| Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant … CJ Logothetis, E Basch, A Molina, K Fizazi, SA North, KN Chi, RJ Jones, ... The lancet oncology 13 (12), 1210-1217, 2012 | 324 | 2012 |
| Rituximab: expanding role in therapy for lymphomas and autoimmune diseases W Rastetter, A Molina, CA White Annu. Rev. Med. 55, 477-503, 2004 | 268 | 2004 |
| Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study LI Gordon, A Molina, T Witzig, C Emmanouilides, A Raubtischek, M Darif, ... Blood 103 (12), 4429-4431, 2004 | 256 | 2004 |
| Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II … ME Taplin, B Montgomery, CJ Logothetis, GJ Bubley, JP Richie, BL Dalkin, ... Journal of clinical oncology 32 (33), 3705, 2014 | 255 | 2014 |
| A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in … A Nademanee, S Forman, A Molina, H Fung, D Smith, A Dagis, C Kwok, ... Blood 106 (8), 2896-2902, 2005 | 249 | 2005 |
